Dyne Therapeutics (DYN) vs Zai Lab (ZLAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Dyne Therapeutics (DYN) has outperformed Zai Lab (ZLAB) over the past year, gaining 14.5% versus a loss of 23.0%. Over five years, DYN leads with a +7.3% price change compared with -75.2% for ZLAB. Dyne Therapeutics is the larger company by market cap ($2.98 billion vs $2.84 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYN | ZLAB |
|---|---|---|
| Share price | $15.97 | $25.31 |
| Market cap | $2.98B | $2.84B |
| 1-day change | +3.70% | -1.06% |
| YTD return | -18.35% | +43.48% |
| 1-year return | +14.48% | -23.05% |
| 5-year return | +7.33% | -75.19% |
| EPS (TTM) | $-3.30 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.31 | $33.97 |
| 52-week low | $13.73 | $15.96 |
| Distance from 52-week high | -41.51% | -25.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +125.42% | +30.94% |
| Average volume | 2.76M | 961.44K |
| Shares outstanding | 186.75M | 112.27M |
| Employees | 289 | 1,784 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYN has outperformed ZLAB by 37.5 percentage points over the past year.
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 289 employees
About Zai Lab
ZLAB stock →Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees
DYN vs ZLAB FAQ
Which is bigger, Dyne Therapeutics or Zai Lab?
Dyne Therapeutics (DYN) is larger, with a market capitalization of $2.98B compared with $2.84B for Zai Lab (ZLAB).
Which stock has performed better over the past year, DYN or ZLAB?
DYN returned +14.48% over the past 12 months, compared with -23.05% for ZLAB (price return, excluding dividends). Past performance does not predict future results.
Are Dyne Therapeutics and Zai Lab in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.